BioMarin Pharmaceutical (BMRN) stock was up nearly 4% in midday trading on the stock market today, after the biotech won an FDA panel vote and announced a new deal with Myriad Genetics (MYGN). Late Tuesday, an advisory panel to the FDA recommended approving Vimizim, a treatment for a rare genetic disease called Morquio syndrome. The disease, which retards growth and causes skeletal deformities, is currently treated only with palliative measures,